A Safety and Efficacy Study of XH001 Combined With Sintilimab Injection in Advanced Solid Tumors

Solid Tumor Clinical Trial

Official title:

A Safety and Efficacy Study of XH001 (Neoantigen Cancer Vaccine) Combined With Sintilimab Injection in Advanced Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05940181
• Other study ID #: XKY-C-001
• Status: Recruiting
• Phase: N/A
• Start date: March 1, 2023
• Est. completion date: December 2025

Study information

• Verified date: July 2023
• Source: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
• Contact: Jianming XU, Dr.
• Phone: 86 10 66937876
• Email: jmxu2003[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an investigator-initiated, single-center, open label, single-arm dose escalation study of XH001 (neoantigen tumor vaccine) in combination with sintilimab for advanced solid tumors. To evaluate the safety and tolerability of XH001 combined with sintilimab in subjects with advanced solid tumors, and preliminarily evaluate the efficacy of the combination therapy in subjects with advanced solid tumors.

The study will include pre-screening period (about 12 weeks), screening period (Weeks -4 to Day 1, and Week -1 to Day -1 will be baseline period), treatment period (Day 1 to Week 16 will be combination treatment period, followed by sintilimab monotherapy), and follow-up period. After signing pre-screening informed consent, tumor tissue and blood samples will be collected for gene sequencing, neoantigen prediction and vaccine preparation. During vaccine preparation, subjects will receive sintilimab (200mg, intravenous infusion, 21-day per cycle) or other antitumor therapy as deemed appropriate by the investigator. Subjects who sign and provide formal informed consent will enter the formal screening period, and qualified subjects will enter treatment period. During the treatment period, subjects will receive 6 cycles of XH001+ sintilimab, followed by sintilimab monotherapy (sintilimab will be administered for up to 18 cycles or for 1 year, whichever comes first).

The dose escalation phase follows standard 3+3 design. 9-12 subjects are expected to be enrolled at 2 given dose level.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 9
• Est. completion date: December 2025
• Est. primary completion date: May 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Is willing and able to provide written informed consent for the trial.

• Is =18 years and = 75 years of age on day of signing informed consent.

• Has a histologically confirmed advanced solid tumor. Subjects must have documented progression after standard therapy or is intolerant of, refuses, or is not eligible for standard therapy.

• Has at least 1 measurable disease lesion as defined by Response Evaluation Criteria in Solid Tumors.

• Has a life expectancy of =12 weeks.

• Has an ECOG performance status of 0-1.

• Has adequate organ function as confirmed by laboratory values listed in the main body of the protocol

Exclusion Criteria:

• Subject who need to receive systemic application of anti-allergic drugs for a long time, or have a history of life-threatening allergic reactions to any vaccine or drug;

• Symptomatic or rapidly progressive central nervous system metastases. Patients with extensive lung metastases resulting in dyspnea; patients with tumors close to or invading major blood vessels or nerves;

• New cerebrovascular accident (including ischemic stroke, hemorrhagic stroke, and transient ischemic attack) within 6 months before screening;

• Subject with acute myocardial infarction within 6 months before screening, or uncontrolled angina, uncontrolled arrhythmia, severe heart failure (see Appendix 3, New York Heart Association Heart Failure Classification Criteria NYHA Class = III) and other cardiovascular diseases;

• Subject who have received treatment with immunomodulatory drugs 4 times before the first vaccination day (D1), including but not limited to: IL-2, CTLA-4 inhibitors, CD40 agonists, CD137 agonists, IFN-a (except for high-risk surgical subjects who use IFN-a as adjuvant therapy, if IFN-a treatment is stopped 4 times before this trial);

• Subject who received blood transfusion, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) before baseline;

• Subject with skin diseases (e.g., psoriasis) at baseline that may prevent the intradermal injection of vaccine into the target area;

• Subject still suffer from adverse reactions (except alopecia and platinum-induced neurotoxicity = grade 2) that have not been restored to CTCAE version 5.0 grade = 1 after previous anti-tumor treatment during the screening period;

• Concomitant use of steroid hormone drugs (tumor or non-tumor related diseases) is required; however, topical application (not applied to the vaccination site) or inhaled steroid drugs are required;

• Subject has an active infection or uncontrollable infection (except for simple urinary tract infection or upper respiratory tract infection) requiring systemic treatment;

• Subjects with positive human immunodeficiency virus antibody, hepatitis B surface antigen and/or hepatitis B core antibody and positive hepatitis B virus deoxyribonucleic acid > 1000 IU/mL, hepatitis C virus antibody, Treponema pallidum-specific antibody in virological monitoring during the screening period;

• Hypertension poorly controlled on treatment (defined as systolic blood pressure = 160 mmHg and/or diastolic blood pressure = 100 mmHg);

• Subject with other malignant tumors within 5 years before the screening period, except for cervical carcinoma in situ, breast carcinoma in situ and cutaneous basal cell carcinoma that have received appropriate treatment and met the recovery criteria;

• Subject with a history of autoimmune diseases [such as, but not limited to:

interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism (hypothyroidism without clinical symptoms or hypothyroidism caused by chemoradiotherapy can be included), subjects with vitiligo or recovered asthma can be included without any intervention, and subjects with asthma requiring bronchodilators for medical intervention cannot be included];

• Subject who has previously received similar therapeutic tumor vaccines;

• Subject with congenital or acquired immunodeficiency;

• Subject still participating in other clinical trials and not enrolled at the screening period;

• Subject who is unable or unwilling to comply with the study protocol due to potential health, mental or social conditions in the opinion of the investigator;

• Other conditions that, in the opinion of the investigator, would make participation in this study inappropriate.

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumor

Intervention

Biological:
• XH001+ sintilimab
During treatment period, subjects will receive 6 cycles of XH001+ sintilimab, followed by sintilimab monotherapy (sintilimab will be administered for up to 18 cycles or for 1 year, whichever comes first).

Locations

Country	Name	City	State
China	PLA General Hospital	Beijing	Beijing

Sponsors (2)

Lead Sponsor	Collaborator
jianming xu	NeoCura

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MTD or Clinical recommended dose		Baseline through 90 days after last XH001 dose, up to 6 months
Primary	DLT	Rate of Dose Limiting Toxicities	Cycle 1, up to 21 days
Primary	Incidence and degree of Adverse Events and Serious Adverse Events [Safety]	Incidence and degree of participants with adverse events(CTCAE 5.0)	Baseline through 90 days after last sintilimab dose, up to 1 year
Secondary	Antigen-Specific T-cell Responses in Peripheral Blood		Baseline through last sintilimab dose, up to 1 year
Secondary	Number of specific immune response T cells	Pharmacodynamics parameter	Baseline through last sintilimab dose, up to 1 year
Secondary	Overall Response Rate (ORR)		up to 2 years
Secondary	Best Overall Response (BOR)		up to 2 years
Secondary	Disease Control Rate (DCR)		up to 2 years
Secondary	Progression Free Survival (PFS)		up to 2 years